{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T14:41:59Z","timestamp":1715006519487},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T00:00:00Z","timestamp":1361836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust Veterinary J"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe the pharmacokinetics of two veterinary formulations of<jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>\u2010thyroxine available in<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>ustralia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A two\u2010phase randomised, crossover, open\u2010label trial followed by a third\u2010phase parallel\u2010dosing trial was conducted in 11 healthy dogs with an investigative oral<jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>\u2010thyroxine liquid formulation and a reference tablet formulation. Blood sampling was done at defined intervals and serum total<jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>\u2010thyroxine concentrations were measured by radioimmunoassay. The post\u2010dose concentrations were plotted as a function of time for each period and the relative bioavailability of the two formulations were compared using a general linear model with factors for dog, phase, sequence and formulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Following oral administration of the reference tablet at the dose of 100\u2009\u03bcg\/kg, a maximum plasma concentration of approximately 96.2\u2009nmol\/L (baseline endogenous corrected) was reached within 3.77\u2009h. For the investigative liquid preparation at a dose of 50\u2009\u03bcg\/kg, the maximum plasma concentration was 60.1\u2009nmol\/L (baseline endogenous corrected), which was reached within 3.59\u2009h.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The geometric mean of the relative bioavailability for the liquid\/tablet product was 1.1, which suggests that the relative bioavailability of thyroxine following administration of tablet or liquid formulation is similar.<\/jats:p><\/jats:sec>","DOI":"10.1111\/avj.12020","type":"journal-article","created":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T07:09:46Z","timestamp":1361862586000},"page":"83-88","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bioavailability of two<scp>L<\/scp>\u2010thyroxine formulations after oral administration to healthy dogs"],"prefix":"10.1111","volume":"91","author":[{"given":"C","family":"Simpson","sequence":"first","affiliation":[{"name":"Veterinary Hospital Faculty of Veterinary Science The University of Melbourne Werribee Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JL","family":"Devi","sequence":"additional","affiliation":[{"name":"Veterinary Hospital Faculty of Veterinary Science The University of Melbourne Werribee Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Whittem","sequence":"additional","affiliation":[{"name":"Veterinary Hospital Faculty of Veterinary Science The University of Melbourne Werribee Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,2,26]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"1751","volume-title":"Textbook of veterinary internal medicine","author":"Scott\u2010Moncrieff JC","year":"2010"},{"key":"e_1_2_7_3_1","first-page":"185","volume-title":"Kirk's current veterinary therapy XIV: small animal practice","author":"Scott\u2010Moncrieff JC","year":"2009"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2007.05.002"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/030098588502200502"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/2046-0481-60-2-88"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2007.00935.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.2460\/ajvr.1993.54.12.2091","article-title":"Pharmacokinetics of L\u2010thyroxine after its oral administration in dogs","volume":"54","author":"Nachreiner RF","year":"1993","journal-title":"Am J Vet Res"},{"key":"e_1_2_7_9_1","unstructured":"VICH Topic GL9 (GCP) Guideline on Good Clinical Practices. International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Products 2001.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/10\/WC500004343.pdf. Accessed January 2013."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/104063870101300202"},{"key":"e_1_2_7_11_1","unstructured":"2000 Center for Drug Evaluation and Research (CDER) Levothyroxine sodium tablets: in vivo pharmacokinetics and bioavailability studies and in vitro dissolution testing"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1201\/b14095"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2008.0236.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.1999.tb03040.x"},{"key":"e_1_2_7_15_1","first-page":"364","volume-title":"Kirk's current veterinary therapy XII: small animal practice","author":"Refsal KR","year":"1995"},{"key":"e_1_2_7_16_1","volume-title":"Canine and feline endocrinology and reproduction","author":"Feldman EC","year":"2007"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-127-5-2190"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2002.tb00082.x"}],"container-title":["Australian Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Favj.12020","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/avj.12020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T13:36:10Z","timestamp":1715002570000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/avj.12020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,26]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1111\/avj.12020"],"URL":"https:\/\/doi.org\/10.1111\/avj.12020","archive":["Portico"],"relation":{},"ISSN":["0005-0423","1751-0813"],"issn-type":[{"value":"0005-0423","type":"print"},{"value":"1751-0813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,26]]},"assertion":[{"value":"2012-09-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-02-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}